These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

213 related items for PubMed ID: 29270749

  • 41.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 42.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 43.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 44.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 45. Identification of Multisialylated LacdiNAc Structures as Highly Prostate Cancer Specific Glycan Signatures on PSA.
    Haga Y, Uemura M, Baba S, Inamura K, Takeuchi K, Nonomura N, Ueda K.
    Anal Chem; 2019 Feb 05; 91(3):2247-2254. PubMed ID: 30669833
    [Abstract] [Full Text] [Related]

  • 46.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 47. Total and Gleason grade 4/5 cancer volumes are major contributors of human kallikrein 2, whereas free prostate specific antigen is largely contributed by benign gland volume in serum from patients with prostate cancer or benign prostatic biopsies.
    Haese A, Graefen M, Steuber T, Becker C, Noldus J, Erbersdobler A, Huland E, Huland H, Lilja H.
    J Urol; 2003 Dec 05; 170(6 Pt 1):2269-73. PubMed ID: 14634394
    [Abstract] [Full Text] [Related]

  • 48.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 49.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 50.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 51.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 52.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 53.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 54.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 55. Combinations of serum prostate-specific antigen and plasma expression levels of let-7c, miR-30c, miR-141, and miR-375 as potential better diagnostic biomarkers for prostate cancer.
    Kachakova D, Mitkova A, Popov E, Popov I, Vlahova A, Dikov T, Christova S, Mitev V, Slavov C, Kaneva R.
    DNA Cell Biol; 2015 Mar 05; 34(3):189-200. PubMed ID: 25521481
    [Abstract] [Full Text] [Related]

  • 56. [The quotient of prostate-specific antigen and prostate volume. Improved differentiation between benign prostatic hyperplasia and locally circumscribed prostate cancer].
    Semjonow A, Hamm M, Rathert P.
    Urologe A; 1993 May 05; 32(3):250-3. PubMed ID: 7685557
    [Abstract] [Full Text] [Related]

  • 57.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 58. Benign prostatic hyperplasia and prostate cancer differentiation via platelet to lymphocyte ratio.
    Kaynar M, Yildirim ME, Gul M, Kilic O, Ceylan K, Goktas S.
    Cancer Biomark; 2015 May 05; 15(3):317-23. PubMed ID: 25586096
    [Abstract] [Full Text] [Related]

  • 59. Preferential autoimmune response in prostate cancer to cyclin B1 in a panel of tumor-associated antigens.
    Dai L, Li J, Ortega R, Qian W, Casiano CA, Zhang JY.
    J Immunol Res; 2014 May 05; 2014():827827. PubMed ID: 24860838
    [Abstract] [Full Text] [Related]

  • 60.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 11.